Reuters: Sanofi mulls nominees for Genzyme board

Suggesting that Sanofi-Aventis is prepping for a possible proxy fight at Genzyme, the French drugmaker has hired a search firm to vet for potential candidates to nominate to Genzyme's board, sources tell Reuters. Report

Suggested Articles

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.